Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Great Valley Advisor Group Inc.

Great Valley Advisor Group Inc. lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 7.9% in the second quarter, Holdings Channel.com reports. The fund owned 7,343 shares of the company’s stock after selling 631 shares during the quarter. Great Valley Advisor Group Inc.’s holdings in Moderna were worth $872,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Moderna by 15.1% in the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after purchasing an additional 5,129,800 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after buying an additional 1,614,460 shares during the period. Capital World Investors increased its position in shares of Moderna by 0.5% in the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after acquiring an additional 18,728 shares in the last quarter. Norges Bank acquired a new stake in shares of Moderna during the fourth quarter valued at approximately $347,565,000. Finally, Mawer Investment Management Ltd. lifted its position in shares of Moderna by 6.7% in the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after acquiring an additional 120,621 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MRNA. Canaccord Genuity Group boosted their target price on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday, May 3rd. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Thursday, August 1st. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. The Goldman Sachs Group reduced their price target on shares of Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, August 2nd. Finally, UBS Group boosted their price objective on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $124.21.

Insider Buying and Selling

In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total transaction of $1,799,400.00. Following the completion of the transaction, the director now owns 2,224,015 shares of the company’s stock, valued at approximately $266,792,839.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total value of $1,799,400.00. Following the completion of the sale, the director now owns 2,224,015 shares in the company, valued at $266,792,839.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 648 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $105,280.56. Following the transaction, the chief financial officer now owns 5,726 shares in the company, valued at $930,303.22. The disclosure for this sale can be found here. In the last ninety days, insiders sold 366,238 shares of company stock worth $51,819,454. 15.70% of the stock is currently owned by insiders.

Moderna Stock Down 1.4 %

Shares of MRNA stock traded down $1.17 on Wednesday, hitting $81.73. The company’s stock had a trading volume of 1,218,736 shares, compared to its average volume of 4,114,294. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91. The stock has a market capitalization of $31.32 billion, a price-to-earnings ratio of -5.29 and a beta of 1.67. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The firm’s fifty day moving average price is $120.34 and its 200-day moving average price is $114.34.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($3.62) earnings per share. Research analysts anticipate that Moderna, Inc. will post -7.46 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.